Aquestive Therapeutics (Formerly known as MonoSolRx)

121 articles with Aquestive Therapeutics (Formerly known as MonoSolRx)

• Aquestive Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Business Highlights on August 7, 2019

  7/18/2019

  Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products based on its proprietary PharmFilm® technology to meet patients' unmet needs and solve therapeutic problems, today announced that it will report results for the second quarter ended June 30, 2019

• Aquestive Therapeutics Completes $70 Million Debt Refinancing

  7/15/2019

  Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive"), today announced that it has completed a private placement of $70 million of 12.5% Senior Secured Notes due June 2025 and warrants, and refinanced its existing credit facility.

• Aquestive Therapeutics to Present at Two Upcoming Investor Conferences - June 7, 2019

  6/7/2019

  Aquestive Therapeutics, Inc. announced that management will present at the JMP Securities Life Sciences Conference to be held in New York, NY on June 19-20 and at the BMO Prescription for Success Healthcare Conference to be held in New York, NY on June 25.

• Aquestive Therapeutics Completes Enrollment in Libervant™ (diazepam buccal film) Crossover Study

  6/4/2019

  Aquestive Therapeutics, Inc. announced it has completed enrollment in a single dose crossover pharmacokinetic trial for Libervant™, which is in development for the management of select patients with refractory epilepsy who require treatment to control episodes of increased seizure activity, or "seizure clusters." The Company also initiated a rolling New Drug Application submission for Libervant in May 2019 with the FDA.

• Aquestive Therapeutics to Present at Two Upcoming Investor Conferences

  5/13/2019

  Aquestive Therapeutics, Inc. announced that management will present at the 2019 RBC Capital Markets Global Healthcare Conference to be held in New York, NY on May 21-22, and the 20th Annual B.

• Aquestive Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights

  5/8/2019

  Aquestive Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2019 and provided an update on recent developments in its business.

• Aquestive Therapeutics Announces Daniel Barber Named to Chief Operating Officer

  5/8/2019

  Aquestive Therapeutics, Inc. announced the appointment of Daniel Barber to the new position of Senior Vice President, Chief Operating Officer of Aquestive Therapeutics.

• Aquestive Therapeutics to Announce First Quarter 2019 Financial Results and Recent Business Highlights on May 8, 2019

  4/17/2019

  Aquestive Therapeutics, Inc. announced that it will report results for the first quarter ended March 31, 2019 and provide a business update on Wednesday, May 8, 2019 before the market open.

• Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application for Riluzole Oral Film for Treatment of ALS

  4/16/2019

  Aquestive Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for the investigational product riluzole oral film, which the Company intends to market under the brand name Exservan™.

• Aquestive Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

  3/25/2019

  Aquestive Therapeutics, Inc. announced that management will present at the H.C. Wainwright Global Life Sciences Conference to be held in London, UK on April 7 - 9.

• Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights

  3/14/2019

  Secured U.S. Food and Drug Administration (FDA) approval and launched the first proprietary commercial product in its epilepsy franchise, SYMPAZAN™ (clobazam) Oral Film

• Aquestive Therapeutics to Present at Oppenheimer's 29th Annual Healthcare Conference

  3/7/2019

  Aquestive Therapeutics, Inc., a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, announced that management will present at Oppenheimer's 29th Annual Healthcare Conference to be held in New York, NY on March 19 - 20.

• Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights on March 14, 2019

  2/19/2019

  Aquestive Therapeutics, Inc. announced that it will report results for the fourth quarter and full year ended December 31, 2018 and provide a business update on Thursday, March 14, 2019 before the market open.

• Aquestive Therapeutics to Present at 2019 BIO CEO & Investor Conference

  2/8/2019

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company, focused on developing and commercializing differentiated products to solve therapeutic problems today announced that management will present at the BIO CEO & Investor Conference to be held in New York, NY on February 11 and 12.

• Aquestive Therapeutics Provides Update Regarding Suboxone® Sublingual Film Litigation

  2/5/2019

  Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focused on developing and commercializing differentiated products to solve therapeutic problems, announced that the U.S. Court of Appeals for the Federal Circuit denied a motion for a rehearing to reinstate the preliminary injunction against Dr.

• Aquestive Therapeutics Provides Update on Licensee, Sunovion Pharmaceuticals Inc.'s Apomorphine Sublingual Film (APL-130277) New Drug Application

  1/31/2019

  APL-130277 is a medicine to treat OFF episodes (the re-emergence or worsening of Parkinson's symptoms otherwise controlled by medications) experienced by people living with Parkinson's disease

• Aquestive Therapeutics Granted Temporary Restraining Order (TRO) Against Alvogen

  1/25/2019

  Aquestive Therapeutics, Inc. (Nasdaq: AQST), today announced that the U.S. District Court for the District of New Jersey has granted a temporary restraining order (TRO) that enjoins Alvogen from initiating any launch activities related to its generic buprenorphine/naloxone sublingual film.

• Aquestive Therapeutics Appoints Gary H. Slatko, M.D. as Chief Medical Officer

  1/3/2019

  Aquestive Therapeutics, Inc. today announced the appointment of Gary H. Slatko as SVP, Chief Medical Officer (CMO). Dr. Slatko will lead clinical and medical affairs for the company, and is reporting to CEO Keith J. Kendall, effective January 2, 2019.

• Aquestive Therapeutics Provides End of Year Business Update, Including Progress of its Proprietary CNS Assets, Financial and Legal Matters

  12/20/2018

  Projects full year 2018 revenues over $67 million, exceeding expectations, and projects end-of-year cash and cash equivalents in the range of $58 million to $60 million

• Aquestive Therapeutics Schedules Business Update Conference Call on December 20, 2018

  12/18/2018

  Aquestive Therapeutics, Inc. today announced that it will provide a business update on Thursday, December 20.